Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Medpace (MEDP)

Medpace Q4 revenue rises 32% to $708.5 million; 2026 revenue forecast set at $2.755B-$2.855B

Positive Impact 3 of 5 earnings Written later

Medpace reported fourth-quarter and full-year 2025 results on February 9, 2026. Revenue and GAAP earnings per diluted share both rose from the prior-year periods, and the company gave a 2026 forecast for revenue, GAAP net income and EBITDA, with the forecast implying slower revenue growth than in 2025.

Key points

  • Q4 2025 revenue was $708.5 million, up 32.0% from $536.6 million; GAAP diluted EPS was $4.67 versus $3.67.
  • Full-year 2025 revenue was $2.53 billion, up 20.0%; GAAP diluted EPS was $15.28 versus $12.63.
  • 2026 guidance: revenue of $2.755 billion to $2.855 billion (8.9% to 12.8% growth) and GAAP diluted EPS of $16.68 to $17.50.
  • No share repurchases in Q4 2025; $821.7 million remained under the buyback program at December 31, 2025.

The filing

CompanyMedpace (MEDP)
Form8-K, current report
Filed with the SECFeb 9, 2026, 4:15 PM ET
Accession number0001668397-26-000004

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.